E. Sevillano Fernandez

LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2023 · 21 citations · Full text

Breast Oncology, Oncology, Medicine +9

761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial

Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández et al. · Annals of Oncology · 2020 · 17 citations · Full text

Surgical Oncology, Urology, Genitourinary Cancer +9

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

Georgina V. Long, Reinhard Dummer, A. Ribas et al. · European Journal of Cancer · 2015 · 16 citations

Phase 1B, Medicine, Melanoma +9

Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.

Piotr Tomczak, Lazar Popović, Philippe Barthélémy et al. · Journal of Clinical Oncology · 2021 · 16 citations

Immunology, Active-control Study, Pharmacotherapy +16

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients

E. Sevillano Fernandez, Rodrigo Madurga, Juan F. Rodríguez-Moreno et al. · Journal of Clinical Medicine · 2022 · 10 citations · Full text